📧 Communication
Company AnnouncementCommunication Details
From
Celgene
Linked to Celgene
To
Public
Public
Subject
Multiple Myeloma
Message Content
Celgene announced it would pursue F.D.A. approval for multiple myeloma. The F.D.A. later reprimanded them for not adequately warning about thalidomide's risks in this announcement.
📄 Source Document
HOUSE_OVERSIGHT_028418.jpg
ESTATE Collection
Document Summary
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein communication